A Real-World Observation of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) in Lymphoma Patients With Chemotherapy Induced Thrombocytopenia

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Sep 7

PMID 34490101

Citations 9

Authors

Qiuhua Zhu

Shimei Yang

Wenbin Zeng

Mingjie Li

Zebing Guan

Lanlan Zhou

Hong Wang

Yanan Liu

Yanmin Gao

Shiqiu Qiu

Chaolun Chen

Huan Li

Shanshan Zheng

Yuemei Yuan

Hanling Zhang

Xueyi Pan

Affiliations

Soon will be listed here.

Abstract

This real-world, observational study aimed to assess and compare the clinical efficacy and safety of eltrombopag with recombinant human thrombopoietin (rhTPO) in the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with lymphoma. One hundred and fifty-three patients who experienced grade 3 or 4 thrombocytopenia after chemotherapy for lymphoma were enrolled, 51 of which were treated with eltrombopag, 50 with rhTPO, and 52 patients with no drug treatment were served as the control group. The lowest platelet level and mean platelet counts at Day 5, Day 7, and Day 10 were significantly higher in both the eltrombopag group (P=.041,.003,.000,.000) and rhTPO group (P=.005,.005,.000,.000) than the control, but there was no difference between treatment with eltrombopag and rhTPO. Similarly, days required for the recovery of platelet counts to ≥50×10/L and ≥75×10/L were not different between the two treatment groups but significantly higher than the control group (P <.05). Rates of bleeding and platelet transfusion were all significantly reduced in patients treated with eltrombopag (P=.031,.032) or rhTPO (P=.017,.009) when compared to the control. Treatment-related adverse events (AEs) were reported in 7 (13.7%) and 6 (12.0%) patients in the eltrombopag and rhTPO groups, respectively, all being mild and transient in nature. In conclusion, both eltrombopag and rhTPO were effective and safe in the treatment of thrombocytopenia after chemotherapy for lymphoma.

Citing Articles

Avatrombopag for the treatment of patients with chemotherapy-induced thrombocytopenia: A case series.

Galamaga R, Johnston S, Acosta C Br J Haematol. 2024; 206(1):272-278.

PMID: 39434457 PMC: 11739760. DOI: 10.1111/bjh.19797.

Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: A meta-analysis.

Gurumurthy G, Kisiel F, Gurumurthy S, Gurumurthy J J Oncol Pharm Pract. 2023; 31(1):4-11.

PMID: 38155484 PMC: 11771093. DOI: 10.1177/10781552231219003.

Hetrombopag plus recombinant human thrombopoietin for chemotherapy-induced thrombocytopenia in patients with solid tumors.

Xia X, Zhou H, Zhang H, Deng W, Li R, Huang Q Res Pract Thromb Haemost. 2023; 7(7):102231.

PMID: 38077816 PMC: 10704501. DOI: 10.1016/j.rpth.2023.102231.

Recombinant human thrombopoietin therapy for primary immune thrombocytopenia in pregnancy: a retrospective comparative cohort study.

Lin J, Wang T, Huang M, Huang H, Chen P, Zhou Y BMC Pregnancy Childbirth. 2023; 23(1):820.

PMID: 38012579 PMC: 10680270. DOI: 10.1186/s12884-023-06134-y.

Supportive Care in Older Lymphoma Patients to Reduce Toxicity and Preserve Quality of Life.

Massaro F, Andreozzi F, Vandevoorde C, Bron D Cancers (Basel). 2023; 15(22).

PMID: 38001641 PMC: 10670135. DOI: 10.3390/cancers15225381.

References

Vadhan-Raj S, Verschraegen C, Bueso-Ramos C, Broxmeyer H, Kudelka A, Freedman R . Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000; 132(5):364-8. DOI: 10.7326/0003-4819-132-5-200003070-00005. View

Kuter D . The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013; 98(1):10-23. DOI: 10.1007/s12185-013-1382-0. View

Nevil G, Roth M, Gill J, Zhang W, Teicher B, Erickson S . Initial testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium. Pediatr Hematol Oncol. 2020; 38(1):8-13. PMC: 8670012. DOI: 10.1080/08880018.2020.1802539. View

Winer E, Safran H, Karaszewska B, Bauer S, Khan D, Doerfel S . Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study. Int J Hematol. 2017; 106(6):765-776. DOI: 10.1007/s12185-017-2319-9. View

Zhang X, Chuai Y, Nie W, Wang A, Dai G . Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours. Cochrane Database Syst Rev. 2017; 11:CD012035. PMC: 6486270. DOI: 10.1002/14651858.CD012035.pub2. View

Bai C, Xu G, Zhao Y, Han S, Shan Y . [A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2004; 26(4):437-41. View

Saleh M, Bussel J, Cheng G, Meyer O, Bailey C, Arning M . Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2012; 121(3):537-45. DOI: 10.1182/blood-2012-04-425512. View

Chawla S, Staddon A, Hendifar A, Messam C, Patwardhan R, Kamel Y . Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. BMC Cancer. 2013; 13:121. PMC: 3605142. DOI: 10.1186/1471-2407-13-121. View

Bai C, Zou X, Zhao Y, Han S, Shan Y . [The clinical study of recombinant human thrombopoietin in the treatment of chemotherapy-induced severe thrombocytopenia]. Zhonghua Yi Xue Za Zhi. 2004; 84(5):397-400. View

10.

Kellum A, Jagiello-Gruszfeld A, Bondarenko I, Patwardhan R, Messam C, Mostafa Kamel Y . A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Curr Med Res Opin. 2010; 26(10):2339-46. DOI: 10.1185/03007995.2010.510051. View

11.

Dai X, Yu J, Liu L, Wu G . [Value of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor]. Zhonghua Zhong Liu Za Zhi. 2008; 30(8):623-5. View

12.

Weycker D, Hatfield M, Grossman A, Hanau A, Lonshteyn A, Sharma A . Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice. BMC Cancer. 2019; 19(1):151. PMC: 6376753. DOI: 10.1186/s12885-019-5354-5. View

13.

Elting L, Rubenstein E, Martin C, Kurtin D, Rodriguez S, Laiho E . Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol. 2001; 19(4):1137-46. DOI: 10.1200/JCO.2001.19.4.1137. View

14.

Xu Y, Song X, Du F, Zhao Q, Liu L, Ma Z . A Randomized Controlled Study of rhTPO and rhIL-11 for the Prophylactic Treatment of Chemotherapy-Induced Thrombocytopenia in Non-Small Cell Lung Cancer. J Cancer. 2018; 9(24):4718-4725. PMC: 6299384. DOI: 10.7150/jca.26690. View

15.

Al-Samkari H, Parnes A, Goodarzi K, Weitzman J, Connors J, Kuter D . A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica. 2020; 106(4):1148-1157. PMC: 8018116. DOI: 10.3324/haematol.2020.251900. View

16.

Bussel J, Kulasekararaj A, Cooper N, Verma A, Steidl U, Semple J . Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. Semin Hematol. 2019; 56(4):262-278. DOI: 10.1053/j.seminhematol.2019.09.001. View

17.

Frey N, Jang J, Szer J, Illes A, Kim H, Ram R . Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. Lancet Haematol. 2019; 6(3):e122-e131. DOI: 10.1016/S2352-3026(18)30231-X. View

18.

Castaman G, Pieri L . Management of thrombocytopenia in cancer. Thromb Res. 2018; 164 Suppl 1:S89-S93. DOI: 10.1016/j.thromres.2018.02.001. View

19.

Kuter D . Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park). 2015; 29(4):282-94. View

20.

Bjorn N, Sigurgeirsson B, Svedberg A, Pradhananga S, Branden E, Koyi H . Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia. Pharmacogenomics J. 2019; 20(2):179-191. DOI: 10.1038/s41397-019-0099-8. View